Antitumor Agent

• US 20080138437A1
• Filed: 01/31/2005
• Published: 06/12/2008
• Est. Priority Date: 02/09/2004
• Status: Abandoned Application

• Current Assignee: Kabushiki Kaisha Sangi
• Original Assignee: Kabushiki Kaisha Sangi
• Inventors: Sakuma, Shuji, Atsumi, Kiminori, Kikukawa, Keiichiro
• Application Number:
  US10/587,966
• Publication Number:
  US 20080138437A1
• Time in Patent Office: Days
• US Class Current: 424/602
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 31/706 containing six-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia

Abstract

Due to the toxicity of antitumor agents, use of antitumor agents is limited, and thus, it is desirable to develop auxiliary agents or antitumor agents that have the effect of reducing toxicity while maintaining the antitumor effect of antitumor agents. The present invention provides antitumor agents mixed with particulate hydroxyapatite as an auxiliary agent.

Claims

1. An antitumor agent comprising an antitumor component blended with hydroxyapatite.

2. The antitumor agent of claim 1, wherein the hydroxyapatite-blended antitumor agent is administered by one or more routes selected from the group consisting of injection, infusion, and oral administration.

3. The antitumor agent of claim 1, wherein the antitumor component is an alkylating agent, an antimetabolite, an antitumor antibiotic, a plant preparation, a hormone preparation, an immunotherapeutic agent, a platinum preparation, or an antitumor agent not classified as above.

4. The antitumor agent of claim 3, wherein the antitumor component is cyclophosphamide, fluorouracil, bleomycin hydrochloride, bleomycin, bleomycin sulfate, etoposide, vincristine sulfate, interferon-β

, cisplatin, carboplatin, nedaplatin, mitomycin C, doxorubicin, nimustine hydrochloride, fluorouracil, carboquone, paclitaxel, melphalan, vinblastine sulfate, dacarbazine, ifosfamide, thiotepa, vinorelbine tartrate, vinorelbine, neocarzinostatin, tegafur, methotrexate, vindesine sulfate, goserelin acetate, sobuzoxane, tretinoin, estramustine sodium phosphate, toremifene citrate, flutamide, hydroxycarbamide, cytarabine ocfosfate, mercaptopurine, tamoxifen citrate, doxifluridine, busulphan, gefinitib, imatinib mesilate, oxaliplatin, UFT, carmofur, aceglatone, anastrozole, ubenimex, fadrozole hydrochloride hydrate, procarbazine hydrochloride, or bicalutamide.

5. The antitumor agent of claim 1, comprising hydroxyapatite with a maximum particle size of 1 μ

m or less.

6. The antitumor agent of claim 1, comprising hydroxyapatite with a maximum particle size of 0.1 μ

m or less.

7. The antitumor agent of claim 2, comprising hydroxyapatite with a maximum particle size of 5 μ

m or less, wherein the antitumor agent is for oral administration.

8. The antitumor agent of claim 2, comprising hydroxyapatite with a maximum particle size of 0.5 μ

m or less, wherein the antitumor agent is for oral administration.

9. The antitumor agent of claim 1, wherein the amount of hydroxyapatite blended is 0.1 to 1000% of the antitumor component.

10. The antitumor agent of claim 1, comprising pulverizing the mixture of antitumor component and hydroxyapatite.